研究者業績

村松 崇

ムラマツ タカシ  (Takashi Muramatsu)

基本情報

所属
藤田医科大学 医学部 医学科 循環器内科学 准教授
学位
博士(医学)(2011年3月 名古屋大学)
博士(医学)(2015年5月 エラスムス大学)

連絡先
takamfujita-hu.ac.jp
J-GLOBAL ID
201501016252332081
researchmap会員ID
7000012709

論文

 114
  • Masataka Yoshinaga, Takashi Muramatsu, Masato Ishikawa, Takuo Toriya, Takashi Uwatoko, Yuji Matsuwaki, Yuko Ukai, Yohei Kobayashi, Katsuyoshi Ito, Hideaki Ota, Hideo Izawa
    Cardiovascular intervention and therapeutics 2024年8月13日  
    Slow-flow or no-reflow phenomenon is a common procedural complication during percutaneous coronary intervention (PCI). Given the presence of fragile plaque or thrombotic materials, we hypothesized that long-time predilatation using a perfusion balloon in conjunction with intracoronary nicorandil administration reduces the risk of slow-flow or no-reflow in patients presenting with acute coronary syndrome (ACS). Subjects were patients presenting with ACS who underwent PCI between April 2020 and April 2022. We retrospectively investigated the incidence of slow-flow or no-reflow during the procedure as well as in-hospital outcomes in comparison between the cases undergoing 3-min predilatation using a perfusion balloon in conjunction with intracoronary nicorandil administration followed by DES implantation (PB group) and those with direct stenting (DS group). Among 439 ACS patients, 36 patients in the PB group and 51 patients in the DS group were examined. Mean age was 70 years and 78.2% was male. Distal protection devices were more frequently used in the DS group than in the PB group (31.3% vs. 11.1%, p = 0.02). The incidence rate of slow-flow or no-reflow was significantly lower in the PB group than in the DS group (2.8% vs. 23.5%; p < 0.01). Six cases (11.7%) in the DS group required intra-aortic balloon pumping (IABP), while none in the PB group required (p < 0.01). In-hospital clinical outcomes did not differ between the two groups. Prolonged perfusion balloon predilatation in conjunction with intracoronary nicorandil administration was safe and feasible. This novel strategy could be an attractive alternative to conventional direct stenting for ACS patients.
  • Eirin Sakaguchi, Hiroyuki Naruse, Yuya Ishihara, Hidekazu Hattori, Akira Yamada, Hideki Kawai, Takashi Muramatsu, Fumihiko Kitagawa, Hiroshi Takahashi, Junnichi Ishii, Masayoshi Sarai, Masanobu Yanase, Yukio Ozaki, Kuniaki Saito, Hideo Izawa
    Heliyon 10(13) e32452 2024年7月15日  
    The CHA2DS2 -VASc score is a vital clinical tool for evaluating thromboembolic risk in patients with atrial fibrillation (AF). This study investigated the efficacy of the CHA2DS2 -VASc score in a cohort of 737 heterogeneous patients (mean age: 63 years) receiving care in cardiac intensive care units (CICUs), with a creatinine-based estimated glomerular filtration rate (eGFR) of ≥60 mL/min/1.73 m2 upon admission and discharge. Incident chronic kidney disease (CKD) was defined as the emergence of a new-onset eGFR<60 mL/min/1.73 m2, accompanied by a decline of >5 mL/min/1.73 m2 compared to that at discharge. The primary endpoint was the incidence of CKD, and the secondary endpoints included all-cause mortality, cardiovascular events, and progression to end-stage kidney disease. In this cohort, 210 (28 %) patients developed CKD. Multivariate analyses revealed that CHA2DS2 -VASc score was a significant independent predictor of incident CKD, regardless of the presence of AF. Integration of CHA2DS2 -VASc scores with eGFR enhanced the predictive accuracy of incident CKD, as evidenced by the improved C-index, net reclassification improvement, and integrated discrimination improvement values (all p < 0.05). Over the 12-month follow-up period, a composite endpoint was observed in 61 patients (8.3 %), with elevated CHA2DS2 -VASc scores being independently associated with this endpoint. In conclusion, CHA2DS2-VASc scores have emerged as robust predictors of both CKD incidence and adverse outcomes. Their inclusion substantially refined the 12-month risk stratification of patients with preserved renal function hospitalized in the CICUs.
  • Hideki Kawai, Sadako Motoyama, Masayoshi Sarai, Yoshihiro Sato, Takahiro Matsuyama, Ryota Matsumoto, Hiroshi Takahashi, Akio Katagata, Yumi Kataoka, Yoshihiro Ida, Takashi Muramatsu, Yoshiharu Ohno, Yukio Ozaki, Hiroshi Toyama, Jagat Narula, Hideo Izawa
    European radiology 34(4) 2647-2657 2024年4月  
    OBJECTIVES: Evaluation of in-stent restenosis (ISR), especially for small stents, remains challenging during computed tomography (CT) angiography. We used deep learning reconstruction to quantify stent strut thickness and lumen vessel diameter at the stent and compared it with values obtained using conventional reconstruction strategies. METHODS: We examined 166 stents in 85 consecutive patients who underwent CT and invasive coronary angiography (ICA) within 3 months of each other from 2019-2021 after percutaneous coronary intervention with coronary stent placement. The presence of ISR was defined as percent diameter stenosis ≥ 50% on ICA. We compared a super-resolution deep learning reconstruction, Precise IQ Engine (PIQE), and a model-based iterative reconstruction, Forward projected model-based Iterative Reconstruction SoluTion (FIRST). All images were reconstructed using PIQE and FIRST and assessed by two blinded cardiovascular radiographers. RESULTS: PIQE had a larger full width at half maximum of the lumen and smaller strut than FIRST. The image quality score in PIQE was higher than that in FIRST (4.2 ± 1.1 versus 2.7 ± 1.2, p < 0.05). In addition, the specificity and accuracy of ISR detection were better in PIQE than in FIRST (p < 0.05 for both), with particularly pronounced differences for stent diameters < 3.0 mm. CONCLUSION: PIQE provides superior image quality and diagnostic accuracy for ISR, even with stents measuring < 3.0 mm in diameter. CLINICAL RELEVANCE STATEMENT: With improvements in the diagnostic accuracy of in-stent stenosis, CT angiography could become a gatekeeper for ICA in post-stenting cases, obviating ICA in many patients after recent stenting with infrequent ISR and allowing non-invasive ISR detection in the late phase. KEY POINTS: • Despite CT technology advancements, evaluating in-stent stenosis severity, especially in small-diameter stents, remains challenging. • Compared with conventional methods, the Precise IQ Engine uses deep learning to improve spatial resolution. • Improved diagnostic accuracy of CT angiography helps avoid invasive coronary angiography after coronary artery stenting.
  • Nozomi Kotoku, Kai Ninomiya, Shinichiro Masuda, Tsung Ying Tsai, Pruthvi C Revaiah, Scot Garg, Shigetaka Kageyama, Shengxian Tu, Ken Kozuma, Hideyuki Kawashima, Yuki Ishibashi, Gaku Nakazawa, Kuniaki Takahashi, Takayuki Okamura, Yosuke Miyazaki, Hiroki Tateishi, Masato Nakamura, Norihiro Kogame, Taku Asano, Shimpei Nakatani, Yoshihiro Morino, Masaru Ishida, Yuki Katagiri, Fernando De Martino, João Tinoco, Patricia O Guimarães, Kengo Tanabe, Yukio Ozaki, Takashi Muramatsu, Pedro A Lemos, Yoshinobu Onuma, Patrick W Serruys
    International journal of cardiology 400 131805-131805 2024年4月1日  
    BACKGROUND: The geographical disparity in the pathophysiological pattern of coronary artery disease (CAD) among patients undergoing percutaneous coronary intervention (PCI) is unknown. OBJECTIVES: To elucidate the geographical variance in the pathophysiological characteristics of CAD. METHODS: Physiological indices derived from angiography-based fractional flow reserve pullbacks from patients with chronic coronary syndrome enrolled in the ASET Japan (n = 206) and ASET Brazil (n = 201) studies, which shared the same eligibility criteria, were analysed. The pathophysiological patterns of CAD were characterised using Murray law-based quantitative flow ratio (μQFR)-derived indices acquired from pre-PCI angiograms. The diffuseness of CAD was defined by the μQFR pullback pressure gradient index. RESULTS: Significant functional stenoses pre-PCI (μQFR ≤0.80) were more frequent in ASET Japan compared to ASET Brazil (89.9% vs. 67.5%, p < 0.001), as were rates of a post-PCI μQFR <0.91 (22.1% vs. 12.9%, p = 0.013). In the multivariable analysis, pre-procedural μQFR and diffuse disease were independent factors for predicting a post-PCI μQFR <0.91, which contributed to the different rates of post-PCI μQFR ≥0.91 between the studies. Among vessels with a post-PCI μQFR <0.91, a consistent diffuse pattern of CAD pre- and post-PCI occurred in 78.3% and 76.7% of patients in ASET Japan and Brazil, respectively; only 6.3% (Japan) and 10.0% (Brazil) of vessels had a major residual gradient. Independent risk factors for diffuse disease were diabetes mellitus in ASET Japan, and age and male gender in Brazil. CONCLUSIONS: There was geographic disparity in pre-procedural angiography-based pathophysiological characteristics. The combined pre-procedural physiological assessment of vessel μQFR and diffuseness of CAD may potentially identify patients who will benefit most from PCI.
  • 坂口 英林, 成瀬 寛之, 石井 潤一, 山田 晶, 河合 秀樹, 村松 崇, 原田 将英, 西村 豪人, 皿井 正義, 簗瀬 正伸, 井澤 英夫
    日本循環器学会学術集会抄録集 88回 PJ043-1 2024年3月  

MISC

 127
  • Takashi Muramatsu, Yoshinobu Onuma, Yao-Jun Zhang, Christos V. Bourantas, Alexander Kharlamov, Roberto Diletti, Vasim Farooq, Bill D. Gogas, Scot Garg, Hector M. Garcia-Garcia, Yukio Ozaki, Patrick W. Serruys
    REVISTA ESPANOLA DE CARDIOLOGIA 66(6) 483-496 2013年6月  
    First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened the applications of percutaneous coronary interventions for the treatment of coronary artery disease. The polymer is an integral part of drug-eluting stents in that, it controls the release of an antiproliferative drug. The main safety concern of first generation drug-eluting stents with permanent polymers-stent thrombosis-has been caused by local hypersensitivity, delayed vessel healing, and endothelial dysfunction. This has prompted the development of newer generation drug-eluting stents with biodegradable polymers or even polymer-free drug-eluting stents. Recent clinical trials have shown the safety and efficacy of drug-eluting stents with biodegradable polymer, with proven reductions in very late stent thrombosis as compared to first generation drug-eluting stents. However, the concept of using a permanent metallic prosthesis implies major drawbacks, such as the presence of a foreign material within the native coronary artery that causes vascular inflammation and neoatherosclerosis, and also impedes the restoration of the vasomotor function of the stented segment. Bioresorbable scaffolds have been introduced to overcome these limitations, since they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. This update article presents the current status of these new technologies and highlights their future perspectives in interventional cardiology. (C) 2012 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S. L. All rights reserved.
  • Christos V. Bourantas, Hector M. Garcia-Garcia, Roberto Diletti, Takashi Muramatsu, Patrick W. Serruys
    AMERICAN HEART JOURNAL 165(6) 869-+ 2013年6月  
    New advances in image and signal processing have allowed the development of numerous invasive and noninvasive imaging modalities that have revealed details of plaque pathology and allowed us to study in vivo the atherosclerotic evolution. Recent natural history of atherosclerosis studies permitted us to evaluate changes in the compositional and morphological characteristics of the plaque and identify predictors of future events. The idea of being able to identify future culprit lesions and passivate these plaques has gradually matured, and small scale studies have provided proofs about the feasibility of this concept. This review article summarizes the recent advances in the study of atherosclerosis, cites the current evidence, highlights our limitations in understanding the evolution of the plaque and in predicting plaque destabilization, and discusses the potentiality of an early invasive sealing of future culprit lesions.
  • Roberto Diletti, Hector M. Garcia-Garcia, Christos V. Bourantas, Robert Jan van Geuns, Nicolas M. Van Mieghem, Pierfrancesco Agostoni, Takashi Muramatsu, Vasim Farooq, Richard Spencer, Jean De Schepper, Mark Pomeranz, Pieter Stella, Patrick W. Serruys
    EUROINTERVENTION 9(1) 125-134 2013年5月  
    Aims: The Svelte Stent Integrated Delivery System (IDS) is a novel fixed-wire thin-strut cobalt-chromium stent characterised by a very low entry profile. The aim of the present study is to evaluate the safety and the feasibility of the Svelte stent IDS implantation in humans. Methods and results: The present investigation is a prospective, multicentre non-randomised single-arm study. The primary endpoint was freedom from major adverse cardiac events (MACE) at 30 days post-procedure. Invasive follow-up was scheduled at six months post implantation. A total of 47 patients were enrolled and serial OCT imaging was performed in a subgroup of 18 patients. At the index procedure the lesion success rate was 97.9% (46 patients), the mean acute gain was 1.56 +/- 0.43 mm with a mean minimum lumen diameter of 2.48 +/- 0.43 mm Post-implantation OCT imaging revealed a minimal mean prolapse area (0.10 +/- 0.06 mm(2)), mean incomplete stent apposition area (0.12 +/- 0.13 mm(2)) and mean intraluminal mass area (0.05 +/- 0.03 mm(2)). Edge dissections were reported in eight cases (mean dissection width 0.17 +/- 0.07 mm proximally and 0.25 +/- 0.24 mm distally). At 30-day clinical follow-up, one case of myocardial infarction was reported. At six months, the angiographic mean in-stent late loss was 0.95 +/- 0.76 mm By OCT, a high percentage of struts was covered (97.6 +/- 15.00 %) with a mean neointimal thickness of 0.31 +/- 0.14 mm, all edge dissections were clinically silent and healed. Target lesion revascularisation (TLR) occurred in 11 patients (23.4%) and clinically driven TLR in three of these patients (6.4%). No cases of death or stent thrombosis were reported during the study. Conclusions: Implantation of the Svelte stent IDS was observed to be safe, feasible and associated with a low acute vascular injury and a high percentage of strut coverage at 6-month follow-up.
  • Bill D. Gogas, Takashi Muramatsu, Hector M. Garcia-Garcia, Christos V. Bourantas, Niels R. Holm, Leif Thuesen, Vasim Farooq, Yoshinobu Onuma, Patrick W. Serruys
    INTERNATIONAL JOURNAL OF CARDIOLOGY 164(3) E35-E37 2013年4月  
  • Chrysafios Girasis, Johan C. H. Schuurbiers, Takashi Muramatsu, Jean-Paul Aben, Yoshinobu Onuma, Satishkumar Soekhradj, Marie-angele Morel, Robert-Jan van Geuns, Jolanda J. Wentzel, Patrick W. Serruys
    EUROINTERVENTION 8(12) 1451-1460 2013年4月  
    Aims: Validation of new three-dimensional (3-D) bifurcation quantitative coronary angiography (QCA) software. Methods and results: Cardiovascular Angiography Analysis System (CAAS 5v10) allows 3-D angiographic reconstructions based on two or more 2-D projection images. Measurements for minimal lumen diameter (MLD), reference vessel diameter (RVD), percent diameter stenosis (DS) and bifurcation angle (BA) were validated against precision manufactured phantom bifurcations. Length measurements were validated against angiographic measurement catheters inserted into a plexiglas bifurcation phantom. In 3-D reconstructions based on two 2-D images, acquired at variable rotation and angulation, accuracy and precision (mean difference +/- SD) of the 11-segment model for MLD, RVD and DS were 0.013+/-0.131 mm, -0.052+/-0.039 mm and -1.08+/-5.13%, respectively; inter-observer variability was 0.141 mm, 0.058 mm and 5.42%, respectively. Adding the antero-posterior (optimal) projection to these basic reconstructions resulted in reduced variability (0.101 mm, 0.041 mm and 3.93% for MLD, RVD and DS, p&lt;0.01 for all) and showed a trend towards improved precision (0.109 mm, 0.031 mm and 4.26%, respectively, p&gt;0.05 for all). In basic reconstructions, accuracy and precision for BA was -1.3+/-5.0 degrees, whereas inter-observer variability was 7.5 degrees; respective measures for length were 0.15+/-0.26 mm and 0.54 mm. Adding the antero-posterior projection resulted in decreased precision (0.47 mm, p&lt;0.01) and increased variability (1.03 mm, p&lt;0.01) for length measurements; precision (5.4 degrees) and variability (7.9 degrees) for BA did not change significantly (p&gt;0.30). Conclusions: Advances in the methodology of 3-D reconstruction and quantitative analysis for bifurcation lesions translated into highly accurate, precise and reproducible measures of diameter, length and BA.
  • Bill D. Gogas, Hector M. Garcia-Garcia, Yoshinobu Onuma, Takashi Muramatsu, Vasim Farooq, Christos V. Bourantas, Patrick W. Serruys
    JACC-CARDIOVASCULAR INTERVENTIONS 6(3) 211-221 2013年3月  
    The concept of edge vascular response (EVR) was first introduced with bare-metal stents and later with radioactive stents of various activity levels. Although radioactive stents reduced intra-stent neointimal hyperplasia and thereby the incidence of in-stent restenosis in a dose-dependent manner, tissue proliferation at the non-irradiated proximal and distal stent edges resulted in the failure of this invasive treatment. The advent of first-and second-generation drug-eluting stents (DES) reduced in-stent restenosis to approximately 5% to 10%, depending on the lesion subset and DES type. When in-segment restenosis (stent and 5-mm proximal and distal margins) occurred, it was most commonly focal and located at the proximal edge. In addition, stent thrombosis, the other main contributing factor for DES failure, seemed in part to be associated with residual plaque presence and underlying tissue composition at the landing zone of the implanted device, particularly if landed in a necrotic core rich milieu. More recently, the introduction of bioresorbable scaffolds for the treatment of coronary artery disease has prompted the re-evaluation of the EVR. This has recently been assessed up to 2-years after implantation of the Absorb bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, California). In general, the EVR consists of a focal but significant proximal lumen loss that in a few instances necessitates target lesion revascularization of a flow-limiting edge stenosis. Herein, we provide an overview of the in vivo evaluation of the EVR with intravascular ultrasound, virtual histology intravascular ultrasound, and the more recently developed optical coherence tomography. Our objective is to highlight the clinical importance of the EVR as a predisposing and contributing factor to device failure with either bare-metal stents, DES, or bioresorbable scaffolds. (J Am Coll Cardiol Intv 2013; 6: 211-21) (C) 2013 by the American College of Cardiology Foundation
  • Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, Haruo Honjo, Naoki Okumura, Kyoko Matsudaira, Kentaro Yamashita, Kengo Maeda, Takashi Muramatsu, Satoshi Shintani, Kunihiro Matsushita, Toyoaki Murohara
    Journal of Hypertension 31(2) 263-270 2013年2月  
    Objective: To clarify whether the impact of normal and high-normal BP (BP) per se on cardiovascular disease (CVD) and all-cause death differs depending on smoking status. Methods and Results: A prospective observational cohort study (median follow-up period: 7.5 years) was performed among 25 077 healthy nondiabetic Japanese men aged 20-61 years (mean age 37.3 years), whose BP was less than 150/95 mmHg and who were not on medication. Hazard ratios (HRs), adjusted by known risk factors and a change in annual BP during the follow-up, were calculated by the Cox proportional model with less than 119/75 mmHg as a reference. Among smokers, CVD events increased significantly from a SBP of 120 mmHg, with HRs of 2.68 (120-129 mmHg), 4.28 (130-139 mmHg), and 11.7 (140-149 mmHg). The CVD events also increased from a DBP of 75 mmHg (P for trend less than 0.0001), with 75-79 mmHg and 90-94 mmHg considered statistically significant. Among noncurrent smokers, 110-149 mmHg (SBP) and 75-89 mmHg (DBP) were not associated with elevated HRs for CVD. The relation between BP and all-cause mortality was similar among both current and noncurrent smokers: 140-149 mmHg (SBP) and 90-94 mmHg (DBP) were significantly associated with elevated risk, and 130-139 mmHg (SBP) among noncurrent smokers associated with elevated risk. Conclusion: Young and middle-aged healthy Japanese individuals with normal and high-normal BP (120-139/75-89 mmHg) were at risk for CVD among smokers, even after adjusting for an annual change in BP. © 2013 Wolters Kluwer Health | Lippincott Williams Wilkins.
  • Farooq V, Serruys PW, Bourantas CV, Zhang YJ, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A, Muramatsu T, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW
    Circulation 128(2) 141-151 2013年  
  • Muramatsu T, Onuma Y, Garc?a-Garc?a HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW
    J Am Coll Cardiol Intv 6(3) 247-257 2013年  
  • Onuma Y, Thuesen L, van Geuns RJ, van der Ent M, Desch S, Fajadet J, Christiansen E, Smits P, Holm NR, Regar E, van Mieghem NM, Borovicanin V, Paunovic D, Senshu K, van Es GA, Muramatsu T, Lee IS, Schuler G, Zijlstra F, Garcia-Garcia HM, Serruys PW
    Eur Heart J 34(14) 1050-1060 2013年  
  • Lee IS, Bourantas CV, Muramatsu T, Gogas BD, Heo JH, Diletti R, Farooq V, Zhang Y, Onuma Y, Serruys PW, Garcia-Garcia HM
    Cardiovasc Ultrasound 11(7) 25 2013年  
  • Onuma Y, Muramatsu T, Girasis C, Kukreja N, Garcia-Garcia HM, Daemen J, Gonzalo N, Piazza N, Einthoven J, van Domburg R, Serruys PW
    Eurointervention 9(8) 916-922 2013年  
  • Takashi Muramatsu, Hector M. Garcia-Garcia, Il Soo Lee, Nico Bruining, Yoshinobu Onuma, Patrick W. Serruys
    CIRCULATION JOURNAL 76(12) 2822-2831 2012年12月  
    Background: The impact of the sampling rate (SR) of optical frequency domain imaging (OFDI) on quantitative assessment of in-stent structures (ISS) such as plaque prolapse and thrombus remains unexplored. Methods and Results: OFDI after stenting was performed in ST-segment elevation myocardial infarction (STEMI) patients using a TERUMO OFDI system (Terumo Europe, Leuven, Belgium) with 160 frames/s and pullback speed of 20 mm/s. A total of 126 stented segments were analyzed. ISS were classified as either attached or non-attached to stent area boundaries. The volume, mean area and largest area of ISS were assessed according to 4 frequencies of SR, corresponding to distances between the analyzed frames of 0.125, 0.25, 0.50 and 1.0 mm. ISS volume was calculated by integrating cross-sectional ISS areas multiplied by each sampling distance using the disk summation method. The volume and mean area of ISS became significantly larger, while the largest area became significantly smaller as sampling distance became larger (1.11 mm(2) for 0.125 mm vs. 1.00 mm(2) for 1.0 mm, P for trend=0.036). In addition, variance of difference was positively associated with increasing width of sampling distance. Conclusions: Quantification of ISS is significantly influenced by the applied frequency of SR. This should be taken into account when designing future OFDI studies in which quantitative assessment of ISS is critical for the evaluation of STEMI patients. (Circ J 2012; 76: 2822-2831)
  • Yoshinobu Onuma, Leif Thuesen, Robert-Jan van Geuns, Martin van der Ent, Gerhard Schuler, Jean Fajadet, Takashi Muramatsu, Felix Zijlstra, Hector Garcia-Garcia, Patrick Serruys
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 60(17) B150-B150 2012年10月  
  • Maria Radu, Lorenz Raeber, Bindu Kalesan, Takashi Muramatsu, Henning Kelbaek, Jung Heo, Erik Jorgensen, Steffen Helqvist, Vasim Farooq, Salvatore Brugaletta, Hector M. Garcia-Garcia, Peter Juni, Kari Saunamaki, Stephan Windecker, Patrick Serruys
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 60(17) B75-B75 2012年10月  
  • Takashi Muramatsu, Yoshinobu Onuma, Hector M. Garcia-Garcia, Vasim Farooq, Marie-Angele Morel, Cecile Dorange, Susan Veldhof, Alexandre Abizaid, Patrick W. Serruys
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 60(17) B12-B12 2012年10月  
  • Roberto Diletti, Vasim Farooq, Takashi Muramatsu, Bill D. Gogas, Hector M. Garcia-Garcia, Robert Jan van Geuns, Patrick W. Serruys
    JACC-CARDIOVASCULAR INTERVENTIONS 5(10) 1089-1090 2012年10月  
  • Kentaro Yamashita, Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, Kengo Maeda, Naoki Okumura, Kyoko Matsudaira, Satoshi Shintani, Takashi Muramatsu, Kunihiro Matsushita, Toyoaki Murohara
    CIRCULATION JOURNAL 76(10) 2435-2442 2012年10月  
    Background: Body fat percentage (BF%) determined by bioelectrical impedance analysis is widely used at home and in medical check-ups. However, the clinical significance of measuring BF% has not been studied in detail. Methods and Results: A cross-sectional study was carried out on a cohort of 10,774 middle-aged Japanese men who had undergone an annual check-up in 2008. Cut-off points were evaluated for body mass index (BMI), waist circumference (WC), and BF% for detecting participants with cardiovascular disease (CVD) risk factors (diabetes mellitus, hypertension, dyslipidemia), and effectiveness compared for each marker's cut-off point. Additionally, the effects of smoking on cut-off points were evaluated. The cut-off points of BMI, WC, and BF% for detecting participants with 1 or more CVD risk factors were 22.7 kg/m(2), 81.4cm, and 20.3%, respectively. The cut-off points of BF% for 1 or more CVD risk factors classified 3.43% more subjects into correct categories than those of BMI (P&lt;0.001). The cut-off points of BMI, WC, and BF% for detecting individuals with 3 CVD risk factors in current smokers were 24.9 kg/m(2), 87.8 cm, and 23.7%, while those in non-smokers were 23.3 kg/m(2), 83.9 cm, and 22.3%, respectively. Conclusions: BF% could be more effective in detecting individuals with early stage CVD risk accumulation than BMI. The cut-off points for current smokers were lower than those for non-smokers in all markers. (Circ J 2012; 76: 2435-2442)
  • T. Nagahiro, T. Kondo, K. Yamashita, T. Muramatsu, K. Matsushita, K. Maeda, S. Shintani, T. Murohara
    EUROPEAN HEART JOURNAL 33 809-809 2012年8月  
  • T. Kondo, K. Yamashita, T. Muramatsu, K. Matsushita, T. Nagahiro, K. Maeda, S. Shintani, T. Murohara
    EUROPEAN HEART JOURNAL 33 679-680 2012年8月  
  • Takashi Muramatsu, Patrick W. Serruys, Yoshinobu Onuma
    EUROPEAN HEART JOURNAL 33(12) 1510-1510 2012年6月  
  • Soji Nishio, Kunihiko Kosuga, Keiji Igaki, Masaharu Okada, Eisho Kyo, Takafumi Tsuji, Eiji Takeuchi, Yasutaka Inuzuka, Shinsaku Takeda, Tatsuhiko Hata, Yuzo Takeuchi, Yoshitaka Kawada, Takeshi Harita, Junya Seki, Shunji Akamatsu, Shinichi Hasegawa, Nico Bruining, Salvatore Brugaletta, Sebastiaan de Winter, Takashi Muramatsu, Yoshinobu Onuma, Patrick W. Serruys, Shigeru Ikeguchi
    CIRCULATION 125(19) 2343-2352 2012年5月  
    Background-The purpose of this study was to evaluate the long-term safety of the Igaki-Tamai stent, the first-in-human fully biodegradable coronary stent made of poly-l-lactic acid. Methods and Results-Between September 1998 and April 2000, 50 patients with 63 lesions were treated electively with 84 Igaki-Tamai stents. Overall clinical follow-up (&gt;10 years) of major adverse cardiac events and rates of scaffold thrombosis was analyzed together with the results of angiography and intravascular ultrasound. Major adverse cardiac events included all-cause death, nonfatal myocardial infarction, and target lesion revascularization/target vessel revascularization. During the overall clinical follow-up period (121 +/- 17 months), 2 patients were lost to follow-up. There were 1 cardiac death, 6 noncardiac deaths, and 4 myocardial infarctions. Survival rates free of all-cause death, cardiac death, and major adverse cardiac events at 10 years were 87%, 98%, and 50%, respectively. The cumulative rates of target lesion revascularization (target vessel revascularization) were 16% (16%) at 1 year, 18% (22%) at 5 years, and 28% (38%) at 10 years. Two definite scaffold thromboses (1 subacute, 1 very late) were recorded. The latter case was related to a sirolimus-eluting stent, which was implanted for a lesion proximal to an Igaki-Tamai stent. From the analysis of intravascular ultrasound data, the stent struts mostly disappeared within 3 years. The external elastic membrane area and stent area did not change. Conclusion-Acceptable major adverse cardiac events and scaffold thrombosis rates without stent recoil and vessel remodeling suggested the long-term safety of the Igaki-Tamai stent.
  • K. Yamashita, H. Yatsuya, T. Muramatsu, H. Toyoshima, T. Murohara, K. Tamakoshi
    NUTRITION & DIABETES 2(4) e33 2012年4月  
    BACKGROUND: Mechanisms underlying coffee's beneficial actions against cardiovascular disease and glucose metabolism are not well understood. Little information is available regarding association between coffee consumption and adipocytokines. OBJECTIVE: We investigated potential associations between coffee consumption and adiponectin, leptin, markers for subclinical inflammation, glucose metabolism, lipids and liver enzymes. We then investigated whether adipocytokines played a role in the association between coffee consumption and these markers. DESIGN AND SUBJECTS: This is a cross-sectional study comprising 2554 male and 763 female Japanese workers. Potential relations between coffee consumption and adipocytokines or other markers were evaluated using a multiple linear regression model adjusted for confounding factors. We evaluated whether adiponectin and leptin partly explain the associations between coffee consumption and each marker by multiple mediation analysis. RESULTS: Coffee consumption showed significant positive associations with adiponectin and total and low-density lipoprotein cholesterol, and inverse associations with leptin, high sensitivity C-reactive protein (hs-CRP), triglycerides and liver enzymes (all P&lt;0.05). An adjustment for adiponectin and leptin significantly attenuated the associations between coffee consumption and hs-CRP or triglycerides, but not for liver enzymes. No associations were observed between coffee consumption and glucose metabolism-related markers. CONCLUSION: Coffee consumption was associated with high adiponectin and low leptin levels. We speculated that adipocytokines mainly explain the associations of coffee consumption with lipids and hs-CRP. Factors other than adipocytokines may explain the association between coffee consumption and liver function. Nutrition and Diabetes (2012) 2, e33; doi:10.1038/nutd.2012.6; published online 2 April 2012
  • Takashi Muramatsu, Kunihiro Matsushita, Kentaro Yamashita, Takahisa Kondo, Kengo Maeda, Satoshi Shintani, Satoshi Ichimiya, Miyoshi Ohno, Takahito Sone, Nobuo Ikeda, Masato Watarai, Toyoaki Murohara
    HYPERTENSION 59(3) 580-U126 2012年3月  
    It has not been fully examined whether angiotensin II receptor blocker is superior to calcium channel blocker to reduce cardiovascular events in hypertensive patients with glucose intolerance. A prospective, open-labeled, randomized, controlled trial was conducted for Japanese hypertensive patients with type 2 diabetes mellitus or impaired glucose tolerance. A total of 1150 patients (women: 34%; mean age: 63 years; diabetes mellitus: 82%) were randomly assigned to receive either valsartan-or amlodipine-based antihypertensive treatment. Primary outcome was a composite of acute myocardial infarction, stroke, coronary revascularization, admission attributed to heart failure, or sudden cardiac death. Blood pressure was 145/82 and 144/81 mm Hg, and glycosylated hemoglobin was 7.0% and 6.9% at baseline in the valsartan group and the amlodipine group, respectively. Both of them were equally controlled between the 2 groups during the study. The median follow-up period was 3.2 years, and primary outcome had occurred in 54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio: 0.97 [95% CI: 0.66-1.40]; P=0 .85). Patients in the valsartan group had a significantly lower incidence of heart failure than in the amlodipine group (hazard ratio: 0.20 [95% CI: 0.06-0.69]; P=0.01). Other components and all-cause mortality were not significantly different between the 2 groups. Composite cardiovascular outcomes were comparable between the valsartan-and amlodipine-based treatments in Japanese hypertensive patients with glucose intolerance. Admission because of heart failure was significantly less in the valsartan group. (Hypertension. 2012; 59: 580-586.). Online Data Supplement
  • Onuma Yoshinobu, Muramatsu Takashi, Kharlamov Alexander
    Cardiovascular intervention and therapeutics 27(3) 151-154 2012年  
  • Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, Haruo Honjo, Yasuhiro Morita, Kengo Maeda, Kentaro Yamashita, Takashi Muramatsu, Satoshi Shintani, Kunihiro Matsushita, Toyoaki Murohara
    CIRCULATION JOURNAL 75(12) 2885-2892 2011年12月  
    Background: Smoking is still a major health problem among males in Japan. The effects of smoking and quitting on mortality and cardiovascular disease (CVD) need updating. Methods and Results: This was a prospective cohort study with a median follow-up of 7.5 years of a total of 25,464 healthy male Japanese workers aged 20-61 years who were not on any medication. The adjusted hazard ratios (HR; 95% confidence interval) for all-cause death were 1.51 (0.73, 2.94), 1.68 (1.07, 2.70), 1.30 (0.70, 2.34), and those for total CVD events 1.91 (0.72, 4.67), 2.94 (1.65, 5.63), and 3.25 (1.69, 6.54) for light smokers (1-10 cigarettes/day), moderate smokers (11-20/day), and heavy smokers (&gt;= 21/day) compared to never-smokers, respectively. Total CVD events increased dose-dependently as the number of cigarettes/day increased. Acute myocardial infarction was increased at any level of smoking. Stroke was increased at a moderate level of smoking. Quitting for &gt;= 4 years, compared with continuing smokers, reduced the HR for all-cause death to 0.64 (0.38, 1.01), and total CVD events to 0.34 (0.17, 0.62). Conclusions: In healthy young- and middle-aged Japanese males, a significant increase in HR for total CVD events was confirmed for a smoking level of 11-20 cigarettes/day. Quitting reduced the HR for total CVD events, with quitting for &gt;= 4 years being statistically significant. A similar trend was observed for all-cause mortality. (Circ J 2011; 75: 2885-2892)
  • Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, Haruo Honjo, Yasuhiro Morita, Kentaro Yamashita, Kengo Maeda, Takashi Muramatsu, Satoshi Shintani, Kunihiro Matsushita, Toyoaki Murohara
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 18(4) 574-580 2011年8月  
    Aim: The association between subjects with metabolic syndrome (MS) who were considered not to require medication by their attending physicians and all-cause mortality, ischemic heart disease (IHD) and cardiovascular disease (CVD) remains unknown and should be clarified. Methods and results: This is an observational longitudinal cohort study with a median follow-up of 7.5 years performed for 25,471 Japanese men aged 20-61 years who were not on medication. We used a modified definition of MS from the Japanese Society of Internal Medicine and the NCEPATPIII, both of which employed body mass index instead of waist circumference. MS was associated with increased rates of all-cause death (adjusted hazard ratio (HR): 4.88 [95% confidence interval, 2.96-7.66]), IHD (3.17 [1.06-7.65]), and CVD (2.63 [1.32-4.72]). In contrast, overweight subjects with no component or one component had similar rates to subjects of normal weight. Any combination of the three MS components was associated with significantly greater rates of all-cause mortality (HR: 3.18-11.2) and IHD (HR: 3.17-8.24), whereas blood pressure elevation plus dyslipidaemia was associated with a significantly higher rate of CVD (HR: 3.27). In any endpoint, MS defined by Japanese criteria had higher HRs than defined by NCEP ATP III criteria. Conclusion: Young and middle-aged Japanese men with MS who had been viewed as not needing medication already showed increased rates of all-cause mortality, IHD and CVD. Additionally, the event rate depended on the specific combination of metabolic syndrome components.
  • Chaochen Wang, Hiroshi Yatsuya, Takashi Nihashi, Takashi Muramatsu, Koji Tamakoshi, Yuanying Li, Kunihiro Matsushita, Yo Hotta, Hiroshi Fukatsu, Hideaki Toyoshima
    INTERNATIONAL JOURNAL OF OBESITY 35 S34-S34 2011年5月  
  • Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, Haruo Honjo, Kengo Maeda, Takashi Muramatsu, Kentaro Yamashita, Satoshi Shintani, Kunihiro Matsushita, Toyoaki Muroahra
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 57(14) E606-E606 2011年4月  
  • Hirohiko Suzuki, Masayuki Shimano, Yukihiko Yoshida, Yasuya Inden, Takashi Muramatsu, Yukiomi Tsuji, Naoya Tsuboi, Haruo Hirayama, Rei Shibata, Toyoaki Murohara
    CLINICAL CARDIOLOGY 33(12) E18-E23 2010年12月  
    Background: Cardiac resynchronization therapy (CRT) has been reported to improve cardiac performance. However, CRT in patients with advanced heart failure is not always accompanied by an improvement in survival rates. We investigated the association between hemodynamic studies and long-term prognosis after CRT. Methods: A total of 68 consecutive patients receiving CRT devices due to advanced heart failure were assessed by hemodynamic study and long-term outcome after implantation of the device. Hemodynamic parameters were measured both with the CRT on and off. Results: Patients demonstrated significant improvement in the maximum first derivative of left ventricular (LV) pressure (LV dP/dt(max)) and QRS duration after periods with the CRT on. During the follow-up period of 34.9 +/- 17.6 months, basal LV dP/dt(max) and isovolemic LV pressure half-time (T(1/2)), but not percent change in LV dP/dt(max), were independent predictors of cardiac mortality or hospitalization due to heart failure after multivariate Cox regression analysis. The Kaplan-Meier survival analysis revealed that patients in the lowest basal LV dP/dt(max) tertile or the longest basal T(1/2) tertile exhibited a significantly higher cardiac-caused mortality or heart failure hospitalization. Conclusions: Lower LV dP/dt(max) or longer T(1/2) independently predicts cardiac mortality or heart failure hospitalization in patients receiving CRT. The assessment of the basal LV dP/dt(max) and T(1/2) could provide useful information in long-term prognosis after CRT.
  • Takahisa Kondo, Shigeki Osugi, Keiko Shimokata, Haruo Honjo, Yasuhiro Morita, Kengo Maeda, Kentaro Yamashita, Takashi Muramatsu, Satoshi Shintani, Kunihiro Matsushita, Toyoaki Murohara
    CIRCULATION 122(21) 2010年11月  
  • 近藤 隆久, 大杉 茂樹, 下方 敬子, 前田 健吾, 村松 崇, 山下 健太郎, 新谷 理, 松下 邦弘, 室原 豊明
    日本心臓病学会誌 5(Suppl.I) 245-245 2010年8月  
  • Kunihiro Matsushita, Takashi Muramatsu, Takahisa Kondo, Kengo Maeda, Satoshi Shintani, Toyoaki Murohara
    JOURNAL OF CARDIOLOGY 56(1) 111-117 2010年7月  
    Background: Inhibitors of the renin angiotensin system are recommended as the first-line medications for diabetic hypertensive patients. However, there is less evidence supporting this recommendation especially among East Asians, a population with a unique distribution of cardiovascular disease compared to the Western population. Methods and results: The NAGOYA HEART Study is a prospective randomized open-label blinded-endpoint study to compare an angiotensin II receptor blocker, valsartan, and a calcium channel blocker, amlodipine, regarding their efficacies on cardiovascular morbidity and mortality in Japanese hypertensive patients with glucose intolerance. Of 1168 eligible patients, we enrolled 1150 patients from October 2004 to January 2009. The participants will be followed for more than a median follow-up period of 3 years. The primary composite endpoint includes myocardial infarction, stroke, coronary revascularization, and admission due to congestive heart failure or sudden cardiac death. Any of these events are adjudicated by an independent committee under blinded information regarding the treatment arm. Secondary endpoints include all-cause mortality, changes in glucose tolerance status, kidney function, left ventricular structure measured by echocardiogram, and incident atrial fibrillation/flutter. The study was registered at ClinicalTrials.gov NCT00129233. Conclusion: The NAGOYA HEART Study will provide us with a relevant insight for appropriate treatment of hypertension with glucose intolerance. (c) 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
  • Takashi Muramatsu, Hiroshi Yatsuya, Hideaki Toyoshima, Satoshi Sasaki, Yuanying Li, Rei Otsuka, Keiko Wada, Yo Hotta, Hirotsugu Mitsuhashi, Kunihiro Matsushita, Toyoaki Murohara, Koji Tamakoshi
    PREVENTIVE MEDICINE 50(5-6) 272-276 2010年5月  
    Objective. To investigate the associations between dietary intake of n-3 polyunsaturated fatty acids (plant-derived alpha-linolenic acid: ALA, and marine-derived eicosapentaenoic and docosahexaenoic acid: EPA + DHA) and insulin resistance (IR) in a lean population with high n-3 PUFA intake.Method. We cross-sectionally studied 3383 Japanese local government workers aged 35-66 in 2002. IR was defined as the highest quartile of homeostasis model assessment, and nutrient intake was estimated from a diet history questionnaire. The odds ratios (ORs) of IR taking the lowest quartile of ALA or EPA + DHA intake as the reference were calculated by logistic regression analysis.Results. Mean age, body mass index (BMI), and dietary ALA, and median of dietary EPA + DHA were 47.9 years, 22.9 kg/m(2), and 1.90 g/day (0.88%E) and 0.77 g/day (0.36%E), respectively. The ORs of IR decreased across the quartiles of ALA intake (multivariate-adjusted OR for Q4 versus Q1 = 0.74, P for trend = 0.01) and the association was observed only in subjects with a BMI of <25 kg/m(2) (P for interaction = 0.033). However EPA + DHA showed no such associations consistently.Conclusion. Higher ALA intake was significantly associated with a lower prevalence of IR in normal weight individuals of middle-aged Japanese men and women. (C) 2010 Elsevier Inc. All rights reserved.
  • Pei Ouyang, Hiroshi Yatsuya, Hideaki Toyoshima, Rei Otsuka, Keiko Wada, Kunihiro Matsushita, Miyuki Ishikawa, Li Yuanying, Yo Hotta, Hirotsugu Mitsuhashi, Takashi Muramatsu, Norikatsu Kasuga, Koji Tamakoshi
    NAGOYA JOURNAL OF MEDICAL SCIENCE 71(3-4) 115-126 2009年9月  
    A 6-month, twice weekly, well-rounded exercise program (47 sessions in total) comprised of a combination of aerobic, resistance and flexibility training was provided for institutionalized older adults aged 60 to 93. We analyzed the data of 18 older adults who could stand and had attended more than 10% of the classes (mean participation rate: 54%) to examine changes in activities of daily living (ADL), physical fitness tests and depressive moods. The mean (+/- standard deviation, range) age of the participants was 71.3 (+/- 15.6, 60-93) in men and 85.9 (+/- 5.8, 72-93) in women. Significant improvement in ADL of the hand manipulation domain and borderline significant improvement in ADL of the mobility domain were observed (McNemar test p=0.011 and 0.072, respectively). A 6-minute walk distance increased significantly from 151.6 m to 236.6 m (p=0.01, paired t-test), and the result of the Soda Pop test, which tests hand-eye coordination, also improved significantly from 35.2 sec to 25.3 sec (p=0.01, paired t-test). These findings suggest that such a program could be effective in improving the ADL and physical fitness of the elderly.
  • Hirotsugu Mitsuhashi, Hiroshi Yatsuya, Kunihiro Matsushita, Huiming Zhang, Rei Otsuka, Takashi Muramatsu, Seiko Takefuji, Yo Hotta, Takahisa Kondo, Toyoaki Murohara, Hideaki Toyoshima, Koji Tarnakoshi
    CIRCULATION JOURNAL 73(4) 667-672 2009年4月  
    Background: Experimental studies have reported that allopurinol protects hypertensive rats from left ventricular hypertrophy (LVH) with negligible effects on blood pressure (BP). Uric acid (UA) was thought to induce cardiomyocyte growth and interstitial fibrosis of the heart, partly via activation of the renin-angiotensin system. In the present study, the relationship between serum UA levels and electrocardiographically-diagnosed LVH (ECG-LVH) was examined in Japanese men not taking medication for hypertension (HTN), which could confound the association. Methods and Results: A total of 3,305 male workers aged 35-66 years (mean age +/- SD, 48.0 +/- 7.1) were studied. LVH was defined as meeting the ECG criteria (ie, Sokolow-Lyon voltage and/or Cornell voltage QRS duration product). Subjects were divided into 3 groups by tertile of serum UA level. The highest tertile (UA range 0.39-0.65mmol/L or 6.6-11.0 mg/dl) had a significantly increased prevalence of LVH compared with the lowest tertile independent of age, body mass index, serum creatinine level, HTN, diabetes and hyperlipidemia (odds ratio 1.58, 95% confidence interval 1.23-2.02, P&lt;0.001). Similar results were obtained in both the normal and high BP subgroups. Conclusions: UA concentration independently and positively associated with ECG-LVH in Japanese men. (Circ J 2009; 73: 667-672)
  • Mitsuhashi Hirotsugu, Morita Yasuhiro, Muramatsu Takashi, Ishii Hideki, Maeda Kengo, Yatsuya Hiroshi, Toyoshima Hideaki, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 73 503-503 2009年3月1日  
  • Mitsuhashi Hirotsugu, Morita Yasuhiro, Muramatsu Takashi, Ishii Hideki, Maeda Kengo, Yatsuya Hiroshi, Toyoshima Hideaki, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 73 191-191 2009年3月1日  
  • Takashi Muramatsu, Hiroshi Yatsuya, Kunihiro Matsushita, Hirotsugu Mitsuhashi, Hideaki Toyoshima, Toyoaki Murohara
    CIRCULATION 118(18) S1136-S1136 2008年10月  
  • Muramatsu Takashi, Matsushita Kunihiro, Mitsuhashi Hirotsugu, Yatsuya Hiroshi, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 72 499-500 2008年3月1日  
  • Mitsuhashi Hirotsugu, Morita Yasuhiro, Matsushita Kunihiro, Muramatsu Takashi, Ishii Hideki, Maeda Kengo, Kondo Takahisa, Yatsuya Hiroshi, Toyoshima Hideaki, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 72 703-703 2008年3月1日  
  • Kunihiro Matsushita, Hiroshi Yatsuya, Koji Tamakoshi, Takashi Muramatsu, Hirotsugu Mitsuhashi, Rei Shibata, Takahisa Kondo, Toyoaki Murohara, Hideaki Toyoshima
    CIRCULATION 116(16) 814-814 2007年10月  
  • 山本 崇之, 泉 雄介, 橋本 踏青, 松本 正弥, 青山 豊, 小椋 康弘, 鈴木 博彦, 山下 健太郎, 村松 崇, 立松 康, 七里 守, 吉田 幸彦, 三輪田 悟, 平山 治雄
    Circulation journal : official journal of the Japanese Circulation Society 71 828-828 2007年4月20日  
  • Nanasato Mamoru, Izumi Yuusuke, Hashimoto Tousei, Matsumoto Masaya, Yamamoto Takashi, Aoyama Yutaka, Yamashita Kentaro, Suzuki Hirohiko, Ogura Yasuhiro, Muramatsu Takashi, Tatematsu Yasushi, Yoshida Yukihiko, Miwata Satoru, Hirayama Haruo
    Circulation journal : official journal of the Japanese Circulation Society 71 290-290 2007年3月1日  
  • Aoyama Yutaka, Yoshida Yukihiko, Matsumoto Masaya, Yamamoto Takashi, Hashimoto Tousei, Suzuki Hirohiko, Ogura Yasuhiro, Muramatsu Takashi, Tatematsu Yasushi, Nanasato Mamoru, Miwata Satoru, Hirayama Haruo, Okada Taro, Murakami Yoshimasa, Tsuboi Naoya, Itoh Teruo, Hirai Makoto, Inden Yasuya, Yamada Takumi, Izawa Hideo, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 71 565-565 2007年3月1日  
  • Suzuki Hirohiko, Yoshida Yukihiko, Hashimoto Tousei, Matsumoto Masaya, Yamamoto Takashi, Aoyama Yutaka, Ogura Yasuhiro, Muramatsu Takashi, Tatematsu Yasuahi, Nanasato Mamoru, Miwata Satoru, Hirayama Haruo, Tsuboi Naoya, Yamashita Kentaro, Okada Tarou, Murakami Yoshimasa, Izawa Hideo, Inden Yasuya, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 71 574-574 2007年3月1日  
  • Yamamoto Takashi, Yoshida Yukihiko, Matsumoto Masaya, Hashimoto Tousei, Aoyama Yutaka, Suzuki Hirohiko, Ogura Yasuhiro, Muramatsu Takashi, Tatematsu Yasushi, Nanasato Mamoru, Miwata Satoru, Hirayama Haruo, Okada Taro, Murakami Yoshimasa, Tsuboi Naoya, Itoh Teruo, Hirai Makoto, Inden Yasuya, Yamada Takumi, Izawa Hideo, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 71 565-565 2007年3月1日  
  • Ogura Yasuhiro, Yoshida Yukihiko, Matsumoto Masaya, Yamamoto Takashi, Hashimoto Tousei, Aoyama Yutaka, Suzuki Hirohiko, Muramatsu Takashi, Tatematsu Yasushi, Nanasato Mamoru, Miwata Satoru, Hirayama Haruo, Okada Taro, Murakami Yoshimasa, Tsuboi Naoya, Itoh Teruo, Hirai Makoto, Inden Yasuya, Yamada Takumi, Izawa Hideo, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 71 572-572 2007年3月1日  
  • Hashimoto Tousei, Izumi Yuusuke, Matsumoto Masaya, Yamamoto Takashi, Aoyama Yutaka, Ogura Yasuhiro, Suzuki Hirohiko, Yamashita Kentaro, Muramatsu Takashi, Tatematsu Yasushi, Nanasato Mamoru, Yoshida Yukihiko, Miwata Satoru, Hirayama Haruo
    Circulation journal : official journal of the Japanese Circulation Society 71 658-658 2007年3月1日  
  • Suzuki Hirohiko, Yoshida Yukihiko, Hashimoto Tousei, Matsumoto Masaya, Yamamoto Takashi, Aoyama Yutaka, Ogura Yasuhiro, Muramatsu Takashi, Tatematsu Yasushi, Nanasato Mamoru, Miwata Satoru, Hirayama Haruo, Tsuboi Naoya, Yamashita Kentaro, Okada Tarou, Murakami Yoshimasa, Izawa Hideo, Indenn Yasuya, Murohara Toyoaki
    Circulation journal : official journal of the Japanese Circulation Society 71 480-480 2007年3月1日  

書籍等出版物

 5

講演・口頭発表等

 10

共同研究・競争的資金等の研究課題

 2

その他教育活動上特記すべき事項

 2
  • 件名
    第6回 心臓血管外科・循環器内科合同勉強会
    終了年月日
    2014/04/27
    概要
    講演:新しい冠動脈治療法 - 生体吸収性ステント -
  • 件名
    第50回藤田保健衛生大学医学部医学教育ワークショップ
    終了年月日
    2014/02/22
    概要
    ワークショップ「学生支援のスキルを向上させるために」に参加した。